2251.HK

Beijing Airdoc Technology Co. Ltd. (2251.HK) announced on Monday that the China Securities Regulatory Commission (CSRC) has approved its plan to convert 50.15 million of its domestic shares into H-shares that can be publicly traded in Hong Kong. The conversion involves company stock held by 26 shareholders.

Airdoc was founded in 2015 as a provider of ophthalmic imaging solutions. Last July it announced the development of its Wanyu Medical Large Model, expanding its services from single-image diagnostics to general medical Q&A and health management. This February, it upgraded the Wanyu model and integrated it with the DeepSeek R1 model.

Airdoc’s revenue fell 23.3% year-on-year to 156 million yuan ($21 million) last year, while its net loss widened significantly from 133 million yuan in 2023 to 255 million yuan last year. The company’s shares have plunged 83.22% since their listing in November 2021, including a 7.95% decline this year.

By Lee Shih Ta

To subscribe to Bamboo Works weekly free newsletter, click here

Recent Articles

Teway makes seasonings

Sichuan Teway spices up Hong Kong’s hot IPO market

The maker of ready-to-cook and hotpot pre-mixed seasonings has filed to list in Hong Kong, positioning itself as a consolidator in China’s huge seasonings market Key Takeaways: Sichuan Teway has…
Andre Juice sells juice concentrate

Andre Juice’s growth stalls after bumper period

China’s leading maker of apple juice concentrate reported its revenue contracted in the third quarter, ending a period of strong gains in the previous year and a half Key Takeaways:…
Fuyao Glass logs double digit growth

Fuyao Glass looks to new era as its founder bows out

The son of celebrated entrepreneur Cao Dewang has formally taken the helm at the automotive glass giant, just as the firm unveiled upbeat quarterly earnings Key Takeaway: The company logged…